Squadron Master Fund LP
All holdings · as of Dec 31, 2025
| Company | Value | % of portfolio |
|---|---|---|
| Climb Bio, Inc.CLYM | $400.0K | 0.2% |
| Traws Pharma, Inc. | $806.3K | 0.4% |
| INVENTIVA SA | $1.40M | 0.6% |
| Avalo Therapeutics, Inc. | $2.36M | 1.1% |
| COMPASS Pathways plcCMPS | $2.68M | 1.2% |
| Pasithea Therapeutics Corp.KTTA | $2.71M | 1.2% |
| WAVE LIFE SCIENCES LTD | $2.98M | 1.3% |
| NextCure, Inc.NXTC | $3.36M | 1.5% |
| Ventyx Biosciences, Inc. | $3.70M | 1.7% |
| EUPRAXIA PHARMACEUTICALS INC. | $3.77M | 1.7% |
| GH RESEARCH PLC | $4.00M | 1.8% |
| BELITE BIO, INCBLTE | $4.16M | 1.9% |
| Lipocine Inc.LPCN | $4.26M | 1.9% |
| Cybin Inc. | $4.29M | 1.9% |
| DBV TECHNOLOGIES S.A.DBVT | $4.60M | 2.1% |
| Xenon Pharmaceuticals Inc. | $4.73M | 2.1% |
| SPRUCE BIOSCIENCES, INC.SPRB | $6.10M | 2.7% |
| Upstream Bio, Inc.UPB | $6.26M | 2.8% |
| TARSUS PHARMACEUTICALS, INC. | $6.55M | 2.9% |
| Terns Pharmaceuticals, Inc. | $7.68M | 3.4% |
| Kodiak Sciences Inc.KOD | $8.16M | 3.6% |
| Inhibikase Therapeutics, Inc. | $8.66M | 3.9% |
| Edgewise Therapeutics, Inc. | $8.69M | 3.9% |
| PALISADE BIO, INC. | $10.57M | 4.7% |
| KalVista Pharmaceuticals Inc | $11.30M | 5.0% |
| ABIVAX SA | $19.55M | 8.7% |
| Maze Therapeutics, Inc. | $20.30M | 9.1% |
| Cogent Biosciences, Inc. | $27.71M | 12.4% |
| Relmada Therapeutics, Inc. | $32.36M | 14.4% |